Bennett L L, Allan P W, Rose L M, Comber R N, Secrist J A
Mol Pharmacol. 1986 Apr;29(4):383-90.
Neplanocin A and aristeromycin are carbocyclic adenosine analogs that differ only in that neplanocin A contains a double bond in the carbocyclic ring, whereas this ring in aristeromycin is saturated. We have compared the metabolism and some of the metabolic effects of neplanocin A and synthetic (+/-)-aristeromycin (C-Ado) in murine leukemia L1210 cells in culture. C-Ado, as shown earlier, was not only converted to its own phosphates but also was metabolized to phosphates of carbocyclic guanosine. Both rapidly proliferating and slowly proliferating or resting cells phosphorylated C-Ado, but C-Ado was not converted to phosphates of carbocyclic guanosine in detectable amounts in cells whose growth had reached a plateau. When the metabolism of neplanocin and C-Ado was examined in the same experiment, both analogs were converted to the triphosphate analogs of ATP; no conversion of neplanocin A to the corresponding carbocyclic analogs of guanine nucleotides was detected, whereas C-Ado was converted to the carbocyclic analog of GTP in amounts that approximated the GTP pool. This difference in metabolism was associated with a marked difference in effects of the two analogs on the utilization of hypoxanthine and guanine which was inhibited by C-Ado but not by neplanocin. The failure of neplanocin A to be converted to analogs of guanine nucleotides apparently is the result of poor capacity of its monophosphate to serve as a substrate for AMP deaminase; the Vmax for deamination of neplanocin-5'-monophosphate by this enzyme was only 5% of that for C-Ado monophosphate. In contrast, neplanocin A was a better substrate than C-Ado for adenosine deaminase.
奈拉滨和阿瑞吡坦是碳环腺苷类似物,它们的区别仅在于奈拉滨在碳环中含有一个双键,而阿瑞吡坦中的这个环是饱和的。我们比较了奈拉滨和合成的(±)-阿瑞吡坦(C-Ado)在培养的小鼠白血病L1210细胞中的代谢及某些代谢效应。如前所示,C-Ado不仅被转化为其自身的磷酸盐,还被代谢为碳环鸟苷的磷酸盐。快速增殖和缓慢增殖或静止的细胞均能将C-Ado磷酸化,但在生长达到平台期的细胞中,未检测到C-Ado转化为可检测量的碳环鸟苷磷酸盐。当在同一实验中检测奈拉滨和C-Ado的代谢时,两种类似物均被转化为ATP的三磷酸类似物;未检测到奈拉滨A转化为相应的鸟嘌呤核苷酸碳环类似物,而C-Ado转化为GTP的碳环类似物的量接近GTP池。这种代谢差异与两种类似物对次黄嘌呤和鸟嘌呤利用的影响存在显著差异相关,C-Ado可抑制这种利用,而奈拉滨则无此作用。奈拉滨A不能转化为鸟嘌呤核苷酸类似物显然是由于其一磷酸酯作为AMP脱氨酶底物的能力较差;该酶对奈拉滨-5'-单磷酸酯脱氨的Vmax仅为C-Ado单磷酸酯的5%。相反,奈拉滨A作为腺苷脱氨酶的底物比C-Ado更好。